Corcept (CORT): +27% On A Huge Beat — But The Guide Needs Lifyorli To Triple. Is CORT a Buy?

Corcept Therapeutics Incorporated (CORT) Q2 2026 — Reported July 29, 2026 after the close for Q2 2026 (three months ended June 30). Revenue $256.1M (+31.7%) vs ~$220M expected, a 16% beat. Diluted EPS $0.36 vs $0.29 a year ago. Operating income $41.3M (+55%). Korlym and its authorized generic $208.6M (+7.3%); Lifyorli (relacorilant) $47.6M in its first quarter on the market, with 1,300+ patients started and 1,000+ prescribers. Full-year 2026 revenue guidance RAISED to $1.1-$1.2B from $950M-$1,050M. Cash and investments $544.6M, zero debt. The stock rose 27.29% on July 30 to $118.32, touching a 52-week high of $122.21 intraday, and closed the week at $114.49. The arithmetic nobody did: that raised full-year guide leaves the second half needing $679-$779M against a first half of $421.1M — an average quarter of $339-$389M versus the $256.1M just printed, a 33-52% sequential step-up. Hold Korlym flat and it implies Lifyorli does $131-$181M a quarter against the $47.6M it just did, roughly 3x in two quarters. Five of the 36 cents came from a 6.4% tax rate. R&D FELL 10.9%. First-half operating cash flow was $16.8M on $421M of revenue, and the first half ran an $8.3M operating loss. On July 10 the Federal Circuit denied rehearing, ending Corcept's patent case against Teva — 81% of revenue is now unprotected. And on December 17 the FDA rules again on the exact application it rejected on December 31, 2025, the day this stock fell 50.4% in one session. THE CALL: TRIM (3/5, A REAL LAUNCH, PRICED FOR A PERFECT ONE) — base-case value ~$80.0 vs ~$114.49 today. KEY METRICS: - CALL: TRIM 3/5 — fair value ~$80 vs $114.49 (-30%). Probability-weighted DCF at a 10% discount rate on 118.4M diluted shares plus $544.6M of net cash: BEAR $22 (a second CRL in December and a Korlym that finally erodes, 0% terminal), BASE $71 ($1.75B of revenue in 2027 building to $2.5B by 2031 with operating margin expanding from 16% to 37%, 2.5% terminal), BULL $157 (Cushing's approved, label expands, $4.35B by 2031). Weighted 30/45/25 = $78. Multiple cross-check: 20x base-case 2028 EPS of $4.75, discounted back = $79. - REVERSE DCF: at $114.49 the enterprise value is $13.01B — 11.3x the midpoint of this year's guided revenue and about 58x the diluted EPS that guide implies (~$1.98). At a 10% discount rate that price asks Corcept to compound free cash flow at 23.8% a year for ten straight years, off a base that produced $16.8M of operating cash flow in the first half. - THE QUARTER: Revenue $256.147M (+31.7% vs $194.430M). Korlym + authorized generic $208.583M (+7.3%). Lifyorli $47.564M (first quarter of availability). Cost of sales $4.061M — a 98.4% gross margin. R&D $53.890M (DOWN 10.9%). SG&A $156.896M (+51.1%, 61.3% of revenue). Operating income $41.300M (16.1% margin vs 13.7%). Net income $42.987M. Diluted EPS $0.36 vs $0.29. - EARNINGS QUALITY: pre-tax income was $45.931M and the tax charge just $2.944M — a 6.4% effective rate. At a normal 21% rate net income would have been $36.3M and diluted EPS $0.31, not $0.36. A $178.7M deferred tax asset sits on the balance sheet, one fifth of total assets. First half 2026: revenue $421.050M, an OPERATING LOSS of $8.301M, diluted EPS of $0.09. - THE GUIDANCE ARITHMETIC: FY26 guided to $1.1-$1.2B against a first half of $421.1M. That leaves H2 at $679-$779M, an average quarter of $339-$389M against the $256.1M just printed (+33% to +52%; +42% at the midpoint). Holding Korlym flat at ~$208.6M/quarter, the guide implies Lifyorli at $131-$181M a quarter versus $47.6M — 2.8x to 3.8x in two quarters. - CASH AND DILUTION: first-half operating cash flow $16.771M on $421.1M of revenue, down from $49.067M a year earlier — 4% cash conversion at a 98% gross margin. Stock-based compensation $52.459M in the half, three times the operating cash generated. Basic shares 105.377M vs diluted 118.385M — a 12.3% option overhang. Zero buybacks in H1 2026 against $130.5M in H1 2025. Cash and investments $544.6M, no debt. - THE LEGAL FILE: on July 10, 2026 the Federal Circuit denied Corcept's petition for rehearing en banc, ending the Teva patent case (the court affirmed non-infringement on February 19); Teva has sold a generic Korlym since January 2024, and 81% of revenue is now unprotected. Teva is separately suing Corcept for antitrust in N.D. Cal. over its specialty-pharmacy arrangement, with part of the case surviving dismissal. A securities class action filed February 20, 2026 alleges misleading statements about the relacorilant NDA. No provision recorded for any of it. - THE BULL CASE: ROSELLA, the Phase 3 in 381 patients, met both dual primary endpoints and cut the risk of death 35%, published in The Lancet; the FDA approved Lifyorli three months early and NCCN made it a preferred regimen within a month. Eight oncology trials are running across platinum-sensitive ovarian, endometrial, cervical, pancreatic and prostate cancer. MONARCH (MASH) and BELLA Part A both read out by year end, as does the European decision. DAZALS showed an 84% reduction in risk of death in year one in ALS. Our own bull case is $157 — above today's price. - STREET: Buy — 14 buy, 9 hold, 3 sell across 26 analysts. Median target $135, about +18% versus the $114.49 close. Post-print revisions were enormous: H.C. Wainwright $95 to $165, Piper Sandler $88 to $165, Canaccord to $161. We DIFFER and are far more CAUTIOUS at ~$80. We ALIGN that the science is good. - THE DATE: December 17, 2026 — the FDA's decision on relacorilant in Cushing's syndrome, resubmitted in June after the December 31, 2025 Complete Response Letter. The stock fell 50.4% in a single session on that first answer, from $70.19 to $34.80 on 20.3 million shares. It bottomed at a $32.15 close on March 13 and has since risen 256%. What to watch: Bullish: FDA approval of relacorilant in Cushing's syndrome on the December 17 PDUFA date, which moves our base case toward $110; or Lifyorli above $130M in Q3 against roughly $156M implied by the guide. Bearish: Lifyorli below $110M in Q3, which would force the full-year guide down within one quarter of being raised; Korlym and authorized generic revenue turning negative as the Teva generic takes share now that the patent case is over; or a second Complete Response Letter in December. Also on YouTube: @ChargedAlpha DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.